Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib combined with PD-1/PD-L1 inhibitors for advanced hepatocellular carcinoma
ChiCTR2100051171Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of donafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: objective response rate. Started Oct 2021; status: recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100051171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051171.